Naqvi, Maria
Utheim, Tor P.
Charnock, Colin
Funding for this research was provided by:
storbyuniversitetet
Oslo University Hospital
OsloMet - Oslo Metropolitan University
Article History
Received: 21 April 2024
Accepted: 11 September 2024
First Online: 28 September 2024
Declarations
:
: Our previous study was approved by the Regional Committee of Medical Research Ethics (REK number: 350387) []. Informed consent was obtained from all participants. No new approval was required for this study.
: Not applicable.
: MN and CC declare that they have no conflicts of interest.TPU: Irrespective of any potential conflicts of interest, for the sake of transparency, Tor Paaske Utheim is co-founder and co-owner of The Norwegian dry eye clinic and the Clinic of eye health, Oslo, Norway, which delivers talks for and/or receives financial support from the following: ABIGO, Alcon, Allergan, AMWO, Bausch&Lomb, Bayer, European school for advanced studies in ophthalmology, InnZ Medical, Medilens Nordic, Medistim, Novartis, Santen, Specsavers, Shire Pharmaceuticals and Thea Laboratories. He has served on the global scientific advisory board for Novartis and Alcon as well as the European advisory board for Shire Pharmaceuticals. Utheim is the Norwegian Global Ambassador for Tear Film and Ocular Surface Society (TFOS), a Board Member of the International Ocular Surface Society, an International Member of the Japanese Lid and Meibomian gland working group (LIME), a Consultant at the Norwegian Association for the Blind and Partially Sighted, the President of the Oslo Society of ophthalmology, and the Editor-in-Chief of Oftalmolog, an eye journal distributed to all eye doctors in the Nordic region since 1980. Besides publishing articles of presumed interest to our readers, Oftalmolog publishes advertisements from pharmaceutical companies, companies selling ophthalmological equipment, and associations organizing conferences and events in ophthalmology. For more information, visit: oftalmolog.com.